273 related articles for article (PubMed ID: 28314412)
1. Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.
Christensen KV; Smith GP; Williamson DS
Prog Med Chem; 2017; 56():37-80. PubMed ID: 28314412
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
Galatsis P
Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
[TBL] [Abstract][Full Text] [Related]
3. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Inhibitors of LRRK2.
Hatcher JM; Choi HG; Alessi DR; Gray NS
Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
[TBL] [Abstract][Full Text] [Related]
5. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
6. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
[TBL] [Abstract][Full Text] [Related]
7. Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2.
Zhu H; Tonelli F; Turk M; Prescott A; Alessi DR; Sun J
Science; 2023 Dec; 382(6677):1404-1411. PubMed ID: 38127736
[TBL] [Abstract][Full Text] [Related]
8. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
Ray S; Liu M
Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
eNeuro; 2019; 6(6):. PubMed ID: 31685675
[TBL] [Abstract][Full Text] [Related]
10. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
11. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
Zhao Y; Dzamko N
Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
[TBL] [Abstract][Full Text] [Related]
13. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
14. Allosteric inhibition of LRRK2, where are we now.
Soliman A; Cankara FN; Kortholt A
Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
[TBL] [Abstract][Full Text] [Related]
15. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.
Gilligan PJ
Curr Top Med Chem; 2015; 15(10):927-38. PubMed ID: 25832719
[TBL] [Abstract][Full Text] [Related]
17. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
[TBL] [Abstract][Full Text] [Related]
18. Targeting LRRK2 in Parkinson's disease: an update on recent developments.
Chan SL; Tan EK
Expert Opin Ther Targets; 2017 Jun; 21(6):601-610. PubMed ID: 28443359
[TBL] [Abstract][Full Text] [Related]
19. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA
Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707
[TBL] [Abstract][Full Text] [Related]
20. QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease.
Sebastián-Pérez V; Martínez MJ; Gil C; Campillo NE; Martínez A; Ponzoni I
J Integr Bioinform; 2019 Feb; 16(1):. PubMed ID: 30763264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
